Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in BOLT held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Sofinnova Investments, Inc. | 138K | $530K | 0.0% | 7.167% | 0.03% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 99K | $380K | +27.7% | 5.133% | 0.00% |
| 3 | Vivo Capital, LLC | 72K | $279K | 0.0% | 3.769% | 0.03% |
| 4 | CITADEL ADVISORS LLC | 57K | $219K | +462.9% | 2.961% | 0.00% |
| 5 | T3 Companies, LLC | 38K | $146K | 0.0% | 1.978% | 0.16% |
| 6 | Board of Trustees of The Leland Stanford Junior University | 36K | $139K | 0.0% | 1.872% | 0.03% |
| 7 | PFIZER INC | 31K | $134K | 0.0% | 1.629% | 0.08% |
| 8 | Lynx1 Capital Management LP | 31K | $119K | 0.0% | 1.603% | 0.01% |
| 9 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 28K | $106K | 0.0% | 1.431% | 0.08% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 19K | $74K | -33.6% | 0.995% | 0.00% |
| 11 | Shay Capital LLC | 15K | $59K | +3.6% | 0.803% | 0.00% |
| 12 | BlackRock, Inc. | 10K | $37K | 0.0% | 0.505% | 0.00% |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 7K | $27K | 0.0% | 0.367% | 0.00% |
| 14 | Nan Fung Group Holdings Ltd | 5K | $19K | -82.9% | 0.260% | 0.01% |
| 15 | MORGAN STANLEY | 3K | $12K | -1.4% | 0.164% | 0.00% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 3K | $12K | 0.0% | 0.161% | 0.00% |
| 17 | NewEdge Advisors, LLC | 3K | $10K | — | 0.132% | 0.00% |
| 18 | Tower Research Capital LLC (TRC) | 2K | $7K | +56.5% | 0.089% | 0.00% |
| 19 | UBS Group AG | 255 | $982 | -67.6% | 0.013% | 0.00% |
| 20 | SBI Securities Co., Ltd. | 130 | $501 | +1200.0% | 0.007% | 0.00% |
| 21 | JPMORGAN CHASE & CO | 42 | $165 | 0.0% | 0.002% | 0.00% |
| 22 | CITIGROUP INC | 41 | $158 | — | 0.002% | 0.00% |
| 23 | BARCLAYS PLC | 6 | $23 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in BOLT — a direct measure of their conviction.
Filings activity in BOLT during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 4.2% | 31.04% | 0.95 pp | $2M | 7.2% |
| Q1 2026 | 24 | +14% | 31.99% | +0.54 pp | $2M | 24% |
| Q4 2025 | 21 | 8.7% | 31.45% | 9.90 pp | $3M | 22% |
| Q3 2025 | 23 | 12% | 41.35% | 5.13 pp | $4M | 17% |
| Q2 2025 | 26 | 16% | 46.48% | 1.40 pp | $5M | 30% |
| Q1 2025 | 31 | 21% | 47.88% | 0.99 pp | $7M | 27% |
| Q4 2024 | 39 | +18% | 48.87% | 0.35 pp | $10M | 18% |
| Q3 2024 | 33 | — | 49.22% | — | $12M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying BOLT stock.
Based on Q2 2026 13F filings, institutional ownership of Bolt Biotherapeutics, Inc. stands at 31.0%, held across 23 reporting institutions.
Sofinnova Investments, Inc. is the largest reported institutional holder of BOLT, with approximately 137,721 shares worth $0.00B as of Q2 2026.
Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of BOLT, including RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for BOLT is 43 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
2 institutions opened new positions in BOLT during Q2 2026, while 3 fully exited. 4 added to existing positions and 17 trimmed.
BOLT institutional ownership fell by 0.95 percentage points quarter-over-quarter, with a net change of -1 holders.
The top 10 institutions account for 92.0% of all reported 13F value in BOLT, and the top 25 account for 100.0%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.